组蛋白修饰异常靶向免疫微环境促进B细胞淋巴瘤发生和发展的分子机制及靶向治疗进展

Progress of molecular mechanisms and targeted therapies of aberrant histone modifications targeting the immune microenvironment of B-cell lymphoma

组蛋白修饰异常是B细胞淋巴瘤的重要发病机制,主要包括组蛋白甲基化和乙酰化异常。近年研究显示,组蛋白修饰异常可通过创造肿瘤支持性免疫微环境促进肿瘤细胞增殖、免疫逃逸等,从而促进淋巴瘤发生、发展。因此,逆转这些异常变化的表观遗传学药物是目前B细胞淋巴瘤的热点研究领域。文章将从B细胞淋巴瘤免疫微环境、组蛋白修饰异常靶向免疫微环境、免疫微生物改变及相关靶向治疗药物进展方面进行综述。

Abnormal histone modifications,mainly including abnormal histone methylation and acetylation,play a crucial role in the pathogenesis of B-cell lymphoma.Recent studies have shown that abnormal histone modifications can promote the development of lymphoma by creating a tumor supportive immune microenvironment to promote tumor proliferation and immune escape.Therefore,drugs targeting histone modification gene abnormalities are currently a hot field of B-cell lymphoma.This article reviews the immune microenvironment of B-cell lymphoma,histone modification abnormalities targeting the immune microenvironment,immunomicrobial alterations,and advances in related targeted therapeutic agents.